Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Therorna (Chinese：圆因生物) recently announced its completion of a Series A financing round worth over CNY 280 million.
This round was led by MSA Capital (Chinese: 和玉资本). Sherpa Healthcare Partners (Chinese: 夏尔巴投资), 3H Health Investment (Chinese: 三正健康投资) and the existing investors Quan Capital (Chinese: 泉创资本) and Cenova Capital (Chinese: 千骥资本) also participated in this round.
The funding will be used to accelerate the construction of its technology platform, the development of its product pipelines, the registration of clinical trials and the expansion of international collaborations.
Founded in Beijing in 2021, Therorna focuses on developing next-generation vaccines and innovative therapies by leveraging its proprietary circular RNA technology platform. Therorna has established a strong pipeline of novel prophylactic and therapeutic drugs which is aimed at addressing high volume of unmet medical needs. So far, it has raised more than CNY 400 million.
Therorna’s competitors include Abogen (Chinese: 艾博生物), Stemirna (Chinese: 斯微生物) and Circode (Chinese: 环码生物).